OctoPlus N.V.

Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.

Publicatie datum 08 jul 2010 - 03:31

Statutaire naam OctoPlus N.V.

Titel OctoPlus announces agreement with a US biotechnology company on its controlled release technology

Bericht OctoPlus N.V. (“OctoPlus” or the “Company”) (Euronext: OCTO), the drug delivery company, announces today that it has signed an agreement with a US biotechnology company relating to the use of OctoPlus’ controlled release technology. Under the contract announced today, OctoPlus will develop a controlled release version of a product currently in clinical development using its proprietary drug delivery technology PolyActive®. The client will reimburse OctoPlus for its activities under the agreement. Further financial terms of the agreement are not disclosed.

Vorige register resultaat

Volgende register resultaat

Gerelateerde downloads

201007080000000001_OctoPlus announces agreement with a US biotechnology company on its controlled release technology.pdf (opens in a new window)

201007080000000001_OctoPlus tekent evaluatiecontract voor zijn technologie met Amerikaans biotechnologiebedrijf.pdf (opens in a new window)

Datum laatste update: 05 juli 2025